Comparison

Ulixertinib European Partner

Item no. HY-15816-5mg
Manufacturer MedChem Express
CASRN 869886-67-9
Amount 5 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 200 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.95
Citations [1]Ward RA, et al. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem. 2015 Jun 11;58(11):4790-801.|[2]Kumar R, et al. Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2016 Jun 5;125:140-4.|[3]Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311.
ACS Comb Sci. 2019 Dec 9;21(12):805-816.|Adv Sci (Weinh). 2022 Oct;9(30):e2200717.|Adv Sci (Weinh). 2024 Nov 20:e2407662.|Biomed Chromatogr. 2020 Oct;34(10):e4923.|Cancer Biol Ther. 2022 Jan 9;1-14.|Cancer Lett. 2024 Nov 26:217339.|Cancer. 2020 Mar 15;126(6):1339-1350.|Cancers (Basel). 2022 Feb 14;14(4):954.|Cancers (Basel). 2022 Mar 19;14(6):1575.|Cell Death Differ. 2024 May 2.|Cell Death Discov. 2022 Aug 17;8(1):365.|Cell Rep Med. 2025 Feb 6:101970.|Cell Rep. 2021 Dec 28;37(13):110174.|Dev Cell. 2020 Sep 14;54(5):608-623.e5.|Front Cell Dev Biol. 2018 Sep 25;6:111.|Innate Immun. 2020 Aug;26(6):505-513.|J Gastroenterol. 2024 Apr 29.|J Invest Dermatol. 2020 Sep 9;S0022-202X(20)32055-8.|J Transl Med. 2025 Feb 28;23(1):244.|Life Sci. 2025 Mar 10:123553.|Matrix Biol. 5 August 2022.|Mol Cell Endocrinol. 2023 Dec 24:582:112140.|Nat Commun. 2022 Jul 14;13(1):4078.|Nat Commun. 2023 May 19;14(1):2859.|Nat Commun. 2023 Nov 2;14(1):6997.|Neoplasia. 2024 Dec 4:59:101085.|Pharmacol Res. 2023 Oct 14:197:106955.|Platelets. 2024 Dec;35(1):2354833.|Research Square Preprint. 2024 Nov 26.|Research Square Print. 2023 Feb 22.|Sci Adv. 2023 Nov 15;9(46):eadi5921.|Sci Data. 2024 Sep 19.|Sci Transl Med. 2021 Jan 27;13(578):eaba7308.|Theranostics. 2022 Oct 3;12(16):7051-7066.|Ulm University. Molecular Medicine Ulm. 2021 Mar.|Cancer Res. 2024 Mar 19.
Smiles O=C(C1=CC(C2=CC(NC(C)C)=NC=C2Cl)=CN1)N[C@@H](C3=CC=CC(Cl)=C3)CO
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias BVD-523,VRT752271
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-Kinase/protease
Manufacturer - Targets
ERK
Shipping Temperature
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight
433.33
Product Description
Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of [1][2].
Manufacturer - Research Area
Cancer
Solubility
DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway
MAPK/ERK Pathway; Stem Cell/Wnt
Isoform
ERK1; ERK2
Clinical information
Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close